Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694117 | 0.91 | POLB (0.38) | TP53TDP1PTGES | |
| Bicarbonate SCHEMBL1079990 | 0.87 | BDKRB2 (0.43) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7601099 | 0.87 | KMT2A (0.45) | BDKRB2TP53 | |
| SCHEMBL1079989 | 0.87 | BDKRB2 (0.41) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12872101 | 0.85 | BDKRB2 (0.41) | BDKRB2ENPP2TP53CYP1A2CYP3A4 | |
| Bicarbonate SCHEMBL1080270 | 0.84 | TP53 (0.40) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3694072 | 0.84 | BDKRB2 (0.37) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1178266 | 0.84 | BDKRB2 (0.41) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3694116 | 0.83 | BDKRB2 (0.34) | BDKRB2TP53CYP1A2CYP3A4CYP2D6 | |
| Bicarbonate SCHEMBL3704950 | 0.83 | C3AR1 (0.41) | BDKRB2TP53PTGESMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | BDKRB2 620/4885ENPP2 825/4885TP53 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.